Musculoskeletal Disorders from Zoledronic Acid in Breast Cancer Treatment
Author Information
Author(s): Zhou Wen-Bin, Zhang Peng-Ling, Liu Xiao-An, Yang Tao, He Wei
Primary Institution: The First Affiliated Hospital with Nanjing Medical University
Hypothesis
What is the impact of zoledronic acid on musculoskeletal disorders in breast cancer patients?
Conclusion
The study found that zoledronic acid treatment is significantly associated with higher rates of arthralgia and bone pain in breast cancer patients.
Supporting Evidence
- Patients treated with zoledronic acid had a higher risk of arthralgia compared to those without treatment.
- The rate of bone pain was significantly higher in patients receiving upfront zoledronic acid compared to those with delayed treatment.
- Musculoskeletal disorders were reported in over 20% of patients treated with zoledronic acid.
Takeaway
This study shows that a medicine called zoledronic acid can cause joint and bone pain in women being treated for breast cancer.
Methodology
A meta-analysis of randomized clinical trials was conducted to assess musculoskeletal disorders associated with zoledronic acid treatment.
Potential Biases
The results were based on unadjusted risk ratios, which may not account for other potential covariates.
Limitations
Most subjects were Caucasians, and some trials were excluded due to lack of data on musculoskeletal disorders.
Participant Demographics
The majority of participants were Caucasian, with few Asians included.
Statistical Information
P-Value
0.466 for heterogeneity
Confidence Interval
1.096-1.232 for arthralgia; 1.149-1.376 for bone pain; 1.135-1.453 for upfront vs delayed ZOL
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website